Red blood cell abnormalities affect how your body carries oxygen and removes waste products, leading to a wide range of symptoms from mild tiredness to serious complications that require ongoing medical attention.

Understanding Treatment Goals for Red Blood Cell Disorders

When someone receives a diagnosis related to red blood cell problems, the first question is often about what can be done. Treatment for red blood cell abnormalities focuses on several important goals: managing symptoms so people can go about their daily lives, preventing serious complications that might harm other organs, and improving overall quality of life. The approach depends heavily on what type of abnormality is present, how severe the condition is, and the individual patient’s circumstances.^[1]

Red blood cells, also called erythrocytes, are disc-shaped cells that travel through blood vessels carrying oxygen from the lungs to every part of your body. Your body produces about 2 million of these cells every second, and they normally live for about 120 days before being broken down and recycled. When something goes wrong with these cells—whether they’re too few, too many, oddly shaped, or not working properly—it affects the body’s ability to transport oxygen and can cause problems throughout the entire system.^[2]

Medical professionals recognize that red blood cell disorders come in many forms. Some people are born with these conditions because they inherited them from their parents, while others develop them during their lifetime due to nutritional deficiencies, chronic diseases, or other factors. The good news is that there are established treatment approaches approved by medical societies, and researchers continue to explore new therapies through clinical trials that may offer additional options in the future.^[1][4]

Standard Medical Treatments for Red Blood Cell Abnormalities

The traditional approach to treating red blood cell disorders varies significantly depending on the specific problem. For conditions where there are too few healthy red blood cells—a situation called anemia—treatment often begins with addressing the underlying cause. Iron deficiency anemia, the most common type, typically requires iron supplementation. This can be taken by mouth as pills or, when necessary, delivered directly into the veins through an IV. Similarly, when vitamin deficiencies cause anemia, supplements of folate (also called folic acid), vitamin B12, or other vitamins may be prescribed.^[1][6]

Nutritional supplements work by giving the body the building blocks it needs to produce healthy red blood cells. Iron is essential because it’s a key component of hemoglobin, the protein inside red blood cells that actually carries oxygen. Without enough iron, the body simply cannot make functional red blood cells. Vitamin B12 and folate are equally important because they help the bone marrow—the spongy tissue inside bones where blood cells are made—produce properly formed cells. When these nutrients are missing, the bone marrow may create abnormally large or malformed cells that don’t work well.^[2]

For inherited conditions like sickle cell disease, where red blood cells become stiff and crescent-shaped, a medication called hydroxyurea is commonly prescribed. This drug helps reduce how often the cells become sickled, which in turn reduces painful episodes called pain crises that occur when these abnormally shaped cells block blood flow. Hydroxyurea can also decrease the need for blood transfusions and hospital visits. Other medications for sickle cell disease include L-glutamine, which helps reduce the frequency of pain crises, and crizanlizumab, which works by preventing sickled cells from sticking to blood vessel walls.^[5][23]

Blood transfusions represent another cornerstone of treatment for red blood cell disorders. During a transfusion, healthy red blood cells from a donor are given to the patient through an IV. This increases the number of functional oxygen-carrying cells in the bloodstream. Some people need only an occasional transfusion, while others with severe conditions may require regular transfusions—sometimes up to 100 units of blood per year. Transfusions can treat sudden complications like severe anemia or prevent future problems like stroke in people with sickle cell disease.^[12][15]

When the spleen becomes enlarged and starts destroying too many red blood cells—a situation that can happen in some red blood cell disorders—doctors may recommend surgical removal of the spleen, called splenectomy. However, this procedure is not appropriate for all conditions and comes with its own risks, including an increased chance of certain infections. Medical professionals now understand that splenectomy must be carefully considered on a case-by-case basis, as it’s not always effective or safe for every patient with a red blood cell abnormality.^[1][17]

Some red blood cell disorders are caused or worsened by the body’s own immune system attacking healthy cells. In these cases, medications that modify the immune response may be used. Corticosteroids are anti-inflammatory drugs that can calm down an overactive immune system. Intravenous immunoglobulin, which is a concentrated solution of antibodies, can also help regulate immune function. These treatments are typically reserved for specific types of red blood cell problems where the immune system is a key part of the disease process.^[1]

The duration of treatment depends entirely on the underlying condition. Someone with iron deficiency anemia might take supplements for a few months until their stores are replenished, while a person with an inherited disorder like thalassemia may need lifelong treatment including regular transfusions. Chronic conditions require ongoing management and regular monitoring through blood tests to track how well treatment is working and to catch any complications early.^[4]

As with all medical treatments, these approaches come with potential side effects. Iron supplements commonly cause stomach upset, constipation, or dark-colored stools. Blood transfusions carry a small risk of allergic reactions and, with repeated transfusions over time, can lead to iron overload in the body. Hydroxyurea may temporarily reduce other blood cell counts, and immune-modifying medications can increase infection risk. Healthcare providers carefully weigh these risks against the benefits for each patient and monitor for complications throughout treatment.^[1]

Innovative Approaches in Clinical Trials

Beyond standard treatments, researchers are actively testing new approaches to treat red blood cell abnormalities through clinical trials. These studies explore cutting-edge therapies that might one day become new options for patients. Clinical trials happen in phases, each designed to answer specific questions. Phase I trials focus primarily on safety—determining whether a new treatment causes harmful effects and finding the appropriate dose. Phase II trials examine whether the treatment actually works to improve the condition. Phase III trials compare the new treatment directly against current standard care to see if it’s better, as effective, or offers other advantages.^[12]

One of the most exciting developments in treating red blood cell disorders is gene therapy. This innovative approach aims to fix the genetic mutations that cause certain inherited blood disorders. For sickle cell disease and beta thalassemia, a gene therapy called CASGEVY (exagamglogene autotemcel) has been developed for people aged 12 and older. This treatment involves taking some of the patient’s own blood stem cells—the cells that give rise to all blood cells—and using advanced gene editing technology to correct the genetic problem. The modified cells are then returned to the patient, where they can produce healthy red blood cells.^[12]

Gene therapy represents a fundamentally different approach because it targets the root cause of the disease rather than just managing symptoms. The process is complex and requires careful preparation, but early results have shown promise. Patients who receive gene therapy may experience improvements in their red blood cell function and a reduction in disease complications. However, this is still a relatively new field, and researchers continue to study long-term outcomes and refine the techniques.

For sickle cell disease specifically, note that a medication called voxelotor (also known by the brand name Oxbryta) was withdrawn from the market in September 2024. This drug had been designed to prevent the sickling of red blood cells, but the manufacturer determined that its benefits did not outweigh the risks in the patient population for which it was approved. This serves as an important reminder that medical treatments are continuously evaluated for safety and effectiveness even after they reach the market.^[5]

Clinical trials for red blood cell disorders are conducted at medical centers around the world, including locations in the United States, Europe, and other regions. These studies typically have specific eligibility requirements related to age, disease severity, previous treatments, and other health factors. Patients interested in participating in research studies can work with their healthcare providers to identify relevant trials and determine whether they might qualify.^[12]

Another area of active research involves developing new medications that work through different mechanisms to improve red blood cell function or production. While specific code names and details of experimental drugs in early trials are constantly evolving, the general approach involves targeting specific molecular pathways that control how red blood cells are made, how they function, or how they’re broken down. Some experimental treatments focus on reducing inflammation, others on protecting cells from damage, and still others on stimulating the bone marrow to produce more healthy cells.

Preliminary results from various clinical trials have shown potential improvements in several areas: some patients experience increases in their red blood cell counts, reductions in symptoms like fatigue and shortness of breath, fewer complications requiring hospitalization, and better overall quality of life. However, it’s crucial to understand that promising results in early trials don’t guarantee that a treatment will ultimately prove effective or receive approval for general use. Many treatments that look good in early studies don’t make it through the full clinical trial process.

Most common treatment methods

• Nutritional supplementation
  • Iron supplements taken by mouth or given through an IV to treat iron deficiency anemia
  • Folate (folic acid) supplements to address vitamin deficiency
  • Vitamin B12 supplementation or injections for deficiency-related anemia
• Medication therapy
  • Hydroxyurea to reduce sickling in sickle cell disease and decrease pain crises
  • L-glutamine to reduce the frequency of pain crises
  • Crizanlizumab to prevent sickled cells from sticking to blood vessel walls
  • Corticosteroids to modify immune system activity in autoimmune-related disorders
  • Intravenous immunoglobulin to regulate immune function
• Blood transfusions
  • Transfer of healthy red blood cells from donors to increase functional cell count
  • Used to treat severe anemia and prevent complications like stroke
  • May be given occasionally or regularly depending on condition severity
• Surgical interventions
  • Splenectomy (surgical removal of the spleen) in selected cases where the spleen is destroying too many red blood cells
• Gene therapy
  • CASGEVY gene editing therapy for sickle cell disease and beta thalassemia in patients 12 years and older
  • Involves modifying patient’s own blood stem cells to correct genetic mutations